Serum antibodies to capsular polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and children.

No abstract is available for this paper.

• Publication year

  1980

• Venue

  Journal of Infectious Diseases

• Publication date

  1980-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/INFDIS/142.6.861PMID 6780634
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunization against poliomyelitis: risk/benefit/cost in a changing context.

  1979cited by this paper
• Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children.

  1979cited by this paper
• Meningococcus group A vaccine in children three months to five years of age. Adverse reactions and immunogenicity related to endotoxin content and molecular weight of the polysaccharide.

  1978cited by this paper
• Group A meningococcal polysaccharide vaccine and course of the group A meningococcal epidemic in Finland.

  1978cited by this paper
• Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the future.

  1978cited by this paper
• Clinical and Serological Evaluation of a Meningococcal Polysaccharide Vaccine Groups A, C, and Y

  1978cited by this paper
• Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.

  1977cited by this paper
• A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria.

  1977cited by this paper
• Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines.

  1977influential reference
• Clinical and Serological Evaluation of Purified Polysaccharide Vaccines Prepared from Neisseria meningitidis Group Y

  1977cited by this paper
• Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland.

  1977cited by this paper
• Effect of group-A meningococcal vaccine in army recruits in Finland.

  1975cited by this paper
• Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants.

  1975cited by this paper
• Duration of antibody responses after vaccination with group C Neisseria meningitidis polysaccharide.

  1975cited by this paper
• Antibody Responses to Meningococcal Polysaccharide Vaccines

  1973cited by this paper
• Immunogenicity of group A and group C meningococcal polysaccharides in human infants.

  1973cited by this paper
• A controlled field trial of a serogroup A meningococcal polysaccharide vaccine.

  1973cited by this paper
• Quantitative Measurement of “Natural” and Immunization-induced Haemophilus influenzas type b Capsular Polysaccharide Antibodies

  1973cited by this paper
• Immunosuppression in children with malaria.

  1972cited by this paper
• Quantitative determination of the human immune response to immunization with meningococcal vaccines.

  1972influential reference
• Meningococcal infections: 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70

  1971cited by this paper
• Studies on immunological paralysis: VI. Thymic-independence of tolerance and immunity to type III pneumococcal polysaccharide

  1971cited by this paper
• Studies on immunological paralysis. 3. Recirculation and antibody-neutralizing activity of 14C-labelled type 3 pneumococcal polysaccharide in paralysed mice.

  1970cited by this paper
• Prevention of meningococcal disease by group C polysaccharide vaccine.

  1970cited by this paper
• HUMAN IMMUNITY TO THE MENINGOCOCCUS

  1969cited by this paper
• HUMAN IMMUNITY TO THE MENINGOCOCCUS

  1969cited by this paper
• A somatic antigen vaccine for the prevention of meningococcal cerebrospinal meningitis.

  1965cited by this paper
• Statistical aspects of the analysis of data from retrospective studies of disease.

  1959cited by this paper
• The effect of variation in molecular weight on the antigenicity of dextran in man.

  1958cited by this paper
• Pneumococcal antigenic polysaccharide substances from human tissues.

  1956cited by this paper
• Pneumococcal antigenic polysaccharide substances from animal tissues.

  1955cited by this paper
• Persistence of antibodies in human subjects injected with pneumococcal polysaccharides.

  1950cited by this paper
• LOCALIZATION OF ANTIGEN IN TISSUE CELLS

  1950cited by this paper
• LOCALIZATION OF ANTIGEN IN TISSUE CELLS III. CELLULAR DISTRIBUTION OF PNEUMOCOCCAL POLYSACCHARIDES TYPES II AND III IN THE MOUSE

  1949cited by this paper
• Prophylactic Vaccination in Epidemic Meningococcal Meningitis

  1932cited by this paper

• COVID-19 and lessons learned from the pandemic wave of meningococcal meningitis (1985-1990).

  2020cites this paper
• Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development

  2018cites this paper
• The Influence of Maternally Derived Antibody and Infant Age at Vaccination on Infant Vaccine Responses: An Individual Participant Meta-analysis

  2017cites this paper
• The development of global vaccine stockpiles.

  2015cites this paper
• Prevention and Control of Meningococcal Disease

  2014cites this paper
• Glycoconjugate vaccines

  2013cites this paper
• Molecular signatures of antibody responses derived from a systems biological study of 5 human vaccines

  2013cites this paper
• Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).

  2013cites this paper
• Morbidity and Mortality Weekly Report

  2012cites this paper
• Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis

  2012cites this paper
• High throughput measurement of antibody and complement mediated immunity to meningococcal disease

  2012cites this paper
• Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines

  2011cites this paper
• Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine.

  2010cites this paper
• Duration of Naturally Acquired Antibody Responses to Blood-Stage Plasmodium falciparum Is Age Dependent and Antigen Specific

  2008cites this paper
• Immunogenicity of Fractional Doses of Tetravalent A/C/Y/W135 Meningococcal Polysaccharide Vaccine: Results from a Randomized Non-Inferiority Controlled Trial in Uganda

  2008cites this paper
• Persistence of protection against invasive bacteria : memory B cell responses in infants after immunisation

  2008cites this paper
• Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?

  2007cites this paper
• An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine.

  2007cites this paper
• 4.31 – Bacterial Carbohydrate-Based Vaccines

  2007cites this paper
• A new approach to the definition of seroconversion following vaccination in a population with high background antibody concentrations.

  2007cites this paper
• Analysis of the Genetic Diversity of Neisseria Meningitidis in South Africa

  2006cites this paper
• PREVENTION OF MENINGOCOCCAL DISEASE

  2006cites this paper
• Prospects for Vaccine Prevention of Meningococcal Infection

  2006cites this paper
• Canada Communicable Disease Report Relevé des maladies transmissibles au Canada

  2006cites this paper
• Capsular Polysaccharide Vaccines Today Summary : Polysaccharide

  2005cites this paper
• Vaccination considerations in the asplenic patient

  2005cites this paper
• Meningococcal conjugate vaccines

  2005cites this paper
• Development and characterization of the immune response induced by peptides and DNA constructs that mimic the capsular polysaccharide of Neisseria meningitidis serogroup C

  2005cites this paper
• Capsular polysaccharide vaccines today

  2005cites this paper
• Chemoprophylaxis for the prevention of bacterial meningitis

  2005cites this paper
• Immunogenicity of Meningococcal ACYW135 Polysaccharide Vaccine in Saudi Children 5 to 9 Years of Age

  2005cites this paper
• Morbidity and Mortality Weekly Report

  2004cites this paper
• Immunologic Hyporesponsiveness to Serogroup C but Not Serogroup A following Repeated Meningococcal A/C Polysaccharide Vaccination in Saudi Arabia

  2004cites this paper
• Meningococcal Vaccines

  2004cites this paper
• The Strategy to Control New Zealand's Epidemic of Group B Meningococcal Disease

  2004cites this paper
• Meningococcal Vaccines

  2004cites this paper
• The meningococcal vaccine--public policy and individual choices.

  2003cites this paper
• Critical analysis of old and new vaccines against N. meningitidis serogroup C, considering the meningococcal disease epidemiology in Brazil.

  2003cites this paper
• Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines.

  2003cites this paper
• Identification of Neisseria lactamica outer membrane proteins protective against meningococcal disease

  2002cites this paper
• Effect of O Acetylation of Neisseria meningitidis Serogroup A Capsular Polysaccharide on Development of Functional Immune Responses

  2002cites this paper
• Vaccine prevention of meningococcal disease, coming soon?

  2001cites this paper
• Tetravalent meningococcal polysaccharide vaccine is immunogenic in adult allogeneic BMT recipients

  2001cites this paper
• Meningococcal vaccines and vaccine developments.

  2001cites this paper
• Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.

  2001cites this paper
• A rebuttal: epidemic and endemic meningococcal meningitis in sub-Saharan Africa can be prevented now by routine immunization with group A meningococcal capsular polysaccharide vaccine.

  2000cites this paper
• Salivary antibody response to vaccination with meningococcal A/C polysaccharide vaccine in previously vaccinated and unvaccinated Gambian children.

  2000cites this paper
• Relationship between Serum Bactericidal Activity and Serogroup-Specific Immunoglobulin G Concentration for Adults, Toddlers, and Infants Immunized with Neisseria meningitidis Serogroup C Vaccines

  2000cites this paper
• Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines.

  2000cites this paper
• Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults.

  2000cites this paper
• Vaccines for prevention of meningococcal disease

  2000cites this paper
• Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood.

  1999cites this paper
• The infant rat model adapted to evaluate human sera for protective immunity to group B meningococci.

  1999cites this paper
• Carbohydrate-based bacterial vaccines

  1999cites this paper
• The epidemiological impact of antimeningococcal B vaccination in Cuba.

  1999cites this paper
• Prophylaxis of bacterial meningitis.

  1999cites this paper
• Meningococcal Vaccines

  1998cites this paper
• PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

  1998cites this paper
• Patterns in the Emergence of Epidemic Meningococcal Disease

  1998cites this paper
• Persistence of antibodies to meningococcal IgA1 protease versus decay of antibodies to group A polysaccharide and Opc protein.

  1997cites this paper
• [Immunologic behavior of meningococcal vaccines].

  1997cites this paper
• Comportamento imunológico das vacinas anti-meningocócicas

  1997cites this paper
• Meningococcal disease prevention and control strategies for practice-based physicians (Addendum: recommendations for college students). Committee on Infectious Diseases.

  1996cites this paper
• Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial.

  1996cites this paper
• The Statistical Analysis of Immunognicity Data in Vaccine atials

  1995cites this paper
• Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992

  1995cites this paper
• Targeted vaccination with meningococcal polysaccharide vaccine in one district of the Czech Republic

  1995cites this paper
• Antibody responses to the capsular polysaccharide of Neisseria meningitidis serogroup B in patients with meningococcal disease

  1995cites this paper
• Immunité naturelle humorale vis-à-vis des méningocoques A et C en France*

  1995cites this paper
• Reactogenicity and safety of meningococcal A and C vaccine in Saudi children.

  1994cites this paper
• Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults

  1994cites this paper
• Meningococcal lipopolysaccharides: virulence factor and potential vaccine component.

  1993cites this paper
• [Immune response to anti-meningococcal vaccines].

  1993cites this paper
• Immunity confered by anti-meningococci vaccines

  1993cites this paper
• Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization.

  1993cites this paper
• Imunidade conferida por vacinas anti-meningocócicas

  1993cites this paper
• Meningococcal lipopolysaccharides: virulence factor and potential vaccine component

  1993cites this paper
• Vaccines Against Bacterial Infections of Children

  1991cites this paper
• Serum antibodies and bacterial meningitis.

  1991cites this paper
• T MENINGITIS IN THE SUDAN: An epidemiological, clinical and laboratory study

  1990cites this paper
• A thymus-independent (type 1) phosphorylcholine antigen isolated from Trichinella spiralis protects mice against pneumococcal infection.

  1990cites this paper
• Features of a large epidemic of group A meningococcal meningitis in Khartoum, Sudan in 1988.

  1990cites this paper
• A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease.

  1990cites this paper
• Clinical features and complications of epidemic group A meningococcal disease in Sudanese children.

  1990cites this paper
• Measurement of the human immune response to meningococcal lipooligosaccharide antigens by using serum to inhibit monoclonal antibody binding to purified lipooligosaccharide

  1990cites this paper
• Meningococcal vaccine--do some children experience side effects?

  1989cites this paper
• Travel Medicine

  1989influential citation
• Postsplenectomy sepsis

  1989cites this paper
• Childhood acute bacterial meningitis in the Sudan: an epidemiological, clinical and laboratory study.

  1989cites this paper
• Special-Use Immunobiologics for Travelers

  1989cites this paper
• Vaccines for prevention of meningococcal disease

  1989cites this paper
• An epidemiological and serological study on duration of protection after meningococcal Group A polysaccharide (APS) vaccination

  1988cites this paper
• Immunogenicity and reactogenicity of four Haemophilus influenzae type b capsular polysaccharide vaccines in Finnish 24-month-old children.

  1988cites this paper
• Men ingococcal infection

  1988cites this paper
• Control of meningococcal epidemics

  1987cites this paper
• Vaccines against encapsulated bacteria: a global agenda.

  1987cites this paper
• Molecular cloning and expression of Neisseria meningitidis class 1 outer membrane protein in Escherichia coli K-12

  1987cites this paper
• Molecular cloning and expression of Neisseria meningitidis class 1 outer membrane protein in Escherichia coli K-12.

  1987cites this paper
• Isotype concentrations of human antibodies to group A meningococcal polysaccharide.

  1986cites this paper
• Vaccination of Children during Treatment for Leukemia

  1986cites this paper